These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21628305)

  • 1. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.
    Neoh CF; Liew D; Slavin M; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    J Antimicrob Chemother; 2011 Aug; 66(8):1906-15. PubMed ID: 21628305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Mycoses; 2017 Nov; 60(11):714-722. PubMed ID: 28699297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain.
    Grau S; Salavert M; Carlos Pozo Laderas J; García Vargas M; Barrueta JA; Mir N
    J Mycol Med; 2013 Sep; 23(3):155-63. PubMed ID: 23849341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
    Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
    BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Intern Med J; 2013 Jun; 43(6):668-77. PubMed ID: 23461421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
    Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
    Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
    Ou HT; Lee TY; Chen YC; Charbonneau C
    BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
    Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):537-544. PubMed ID: 29185089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.
    Masterton RG; Casamayor M; Musingarimi P; van Engen A; Zinck R; Odufowora-Sita O; Odeyemi IA
    J Med Econ; 2013 Nov; 16(11):1344-56. PubMed ID: 24003830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anidulafungin for the treatment of invasive candidiasis.
    Mayr A; Aigner M; Lass-Flörl C
    Clin Microbiol Infect; 2011 Mar; 17 Suppl 1():1-12. PubMed ID: 21251147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China.
    Chen D; Wan X; Kruger E; Chen C; Yue X; Wang L; Wu J
    J Med Econ; 2018 Mar; 21(3):301-307. PubMed ID: 29303621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anidulafungin versus fluconazole for invasive candidiasis.
    Reboli AC; Rotstein C; Pappas PG; Chapman SW; Kett DH; Kumar D; Betts R; Wible M; Goldstein BP; Schranz J; Krause DS; Walsh TJ;
    N Engl J Med; 2007 Jun; 356(24):2472-82. PubMed ID: 17568028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost and resource utilization associated with fluconazole as first-line therapy for invasive candidiasis: a retrospective database analysis.
    Craver CW; Tarallo M; Roberts CS; Blanchette CM; Ernst FR
    Clin Ther; 2010 Dec; 32(14):2467-77. PubMed ID: 21353115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives.
    Neoh CF; Slavin M; Chen SC; Stewart K; Kong DC
    Int J Antimicrob Agents; 2014 Mar; 43(3):207-14. PubMed ID: 24670423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
    Krause DS; Simjee AE; van Rensburg C; Viljoen J; Walsh TJ; Goldstein BP; Wible M; Henkel T
    Clin Infect Dis; 2004 Sep; 39(6):770-5. PubMed ID: 15472806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.
    Kett DH; Shorr AF; Reboli AC; Reisman AL; Biswas P; Schlamm HT
    Crit Care; 2011; 15(5):R253. PubMed ID: 22026929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1777-1784. PubMed ID: 29959610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.